Incretin-based Combination Therapy in Type 2 Diabetes Mellitus
نویسندگان
چکیده
منابع مشابه
Incretin-based Therapy in the Management of Type 2 Diabetes
Type 2 diabetes is a progressive disease due to reduced beta cell mass, which results in the failure of traditional treatment and the need for more intensive therapeutical measures to maintain a good glycaemic control. Within the last decade there was a preoccupation for developing new classes of drugs to achieve several goals: glycaemic control, weight loss and to preserve residual beta cell m...
متن کاملIncretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease that increases significantly cardiovascular morbidity and mortality. It is associated with obesity, insulin resistance, beta-cell dysfunction, and hyperglucagonemia, the combination of which typically leads to hyperglycemia. Incretin-based treatment modalities, and in particular glucagon-like peptide 1 (GLP-1) receptor agoni...
متن کاملEffects of combination lipid therapy in type 2 diabetes mellitus.
BACKGROUND We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease. METHODS We randomly assigned 5518 patients with type 2 diabetes who were being treated with open-label simvastatin to receive either ...
متن کاملIntegrating incretin-based therapy into type 2 diabetes management.
LEARNING OBJECTIVES 1. Explain the concept of the incretin effect and describe defects in incretin secretion and incretin action that occur in type 2 diabetes mellitus (T2DM) 2. Provide an overview of the rationale and role of incretin-based therapy as described in current practice guidelines for the management of patients with T2DM 3. Compare the efficacy, safety, and tolerability of the incre...
متن کاملAddition of incretin therapy to metformin in type 2 diabetes.
Incretin-based therapies offer a new approach for the management of type 2 diabetes, with a mechanism of action distinct from any existing class of glucose-lowering agents. These drugs improve the body's ability to control blood glucose by increasing active concentrations of glucagon-like peptide-1 (GLP-1). Two approaches have been used to enhance the action of GLP-1. First, incretin mimetics (...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Korean Medical Association
سال: 2009
ISSN: 1975-8456
DOI: 10.5124/jkma.2009.52.10.1030